{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.34","upperLimit":"0.64","value":"0.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"The decision to perform second-look surgery should be based on the physical examination and imaging studies at Week 12 and should only be considered if a reasonable functional and cosmetic result is anticipated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Stage I group III nonorbit primary or stage III group I/II patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)\n\ndactinomycin: Given IV\n\ncyclophosphamide: Given IV\n\nvincristine sulfate: Given IV\n\nradiation therapy: Undergo radiotherapy","id":"OG000","title":"Regimen II (Stage I Group III Nonorbit or Stage III Group I/II"}],"paramType":"NUMBER","populationDescription":"All eligible Stage I Group III nonorbit primary and stage III group I/II patients","reportingStatus":"POSTED","timeFrame":"At 13 weeks after induction","title":"Percentage of Patients With Delayed Surgical Procedures","type":"SECONDARY","unitOfMeasure":"percentage of participants"}